<DOC>
	<DOCNO>NCT01420965</DOCNO>
	<brief_summary>Background : - Sipuleucel-T new treatment advanced stage prostate cancer . It take cell person prostate cancer treat laboratory . Then return cell person help immune system fight cancer . Sipuleucel-T may combine drug CT-011 boost ability kill cancer cell . The chemotherapy drug cyclophosphamide also give , either cell collect start treatment . Objectives : - To test effectiveness Sipuleucel-T , CT-011 , cyclophosphamide prostate cancer . Eligibility : - Men least 18 year age advance prostate cancer . Design : - Participants screen medical history , physical exam , blood urine test , image study . - This study two part , different participant part . All participant monitor frequent blood test image study . - Part I : - Participants provide cell Sipuleucel-T treatment three time . The first time 3 day chemotherapy . The second time 10 day chemotherapy . The third time 24 day chemotherapy . - Participants one dose cyclophosphamide day first dose Sipuleucel-T. - Participants Sipuleucel-T 3 day cell donation . - Part II : - Participants three group : Sipuleucel-T give alone , give CT-011 , give cyclophosphamide CT-011 . - Participants provide cell Sipuleucel-T treatment three time , Part I . - Participants Sipuleucel-T 3 day cell donation , receive treatment drug direct study doctor .</brief_summary>
	<brief_title>Sipuleucel-T , CT-011 , Cyclophosphamide Advanced Prostate Cancer</brief_title>
	<detailed_description>Background : - Prostate cancer common cancer second lead cause cancer death among male Western country . - Sipuleucel-T , recently FDA approve treatment prostate cancer , design induce immune response target PAP , antigen express prostate cancer . . - Blockade PD-1/PD-L1 show enhance therapeutic efficacy peptide cancer vaccines pre-clinical animal model . CT-011 humanize IgG1 kappa recombinant monoclonal antibody PD-1 receptor block interaction PD-L1 PD-1 . - Preclinical study demonstrate CT-011 administer low dose cyclophosphamide lead synergistic antitumor effect combine HPV16 E749-57 peptide vaccine . - Given role CT-011 play down-regulating peripheral tolerance synergistic relationship cyclophosphamide , study propose treat patient advance , castrate-resistant disease CT-011 low-dose cyclophosphamide adjuvant combination Provenge ( Trademark ) activate cell vaccine . Objectives : - To assess feasibility administration Sipuleucel-T ( Provenge ( Trademark ) ) autologous active cellular immunotherapy combination low dose cyclophosphamide men advance castrate-resistant ( hormone refractory ) prostate cancer . - To determine immune efficacy Sipuleucel-T ( Provenge ( Trademark ) ) autologous active cellular immunotherapy alone vs. Sipuleucel-T ( Provenge ( Trademark ) ) combination CT- 011 vs. Sipuleucel-T ( Provenge ( Trademark ) ) combination low-dose cyclophosphamide CT-011 change PA2024-specific IFN- ? ELISPOT responses men advance , castrate-resistant prostate cancer . - Secondary objective determine tolerability toxicity combination low-dose cyclophosphamide/CT-011/ Sipuleucel-T ( Provenge ( Trademark ) ) determine preliminary fashion whether regimen correlate increase progression-free survival ( PFS ) overall survival ( OS ) patient growth rate exploratory fashion . Eligibility : - Males great equal 18 year old chemotherapy na metastatic progressive castrate-resistant prostate cancer define progressive disease ( two consecutively rise PSA value minimum 1-week interval ( 2.0 ng/mL minimum start value PSA ) , appearance one new lesion bone scan , progressive disease Recist 1.1 ) . - Must meet minimum organ safety requirement length time since prior therapy . - May active infection , autoimmune disease require immunosuppressive therapy . Design : Part 1 : Initially feasibility generate Sipuleucel-T administration low dose cyclophosphamide , evaluate use standard 3 + 3 design dos cyclophosphamide 250 mg/m2 125 mg/m2 . Initially 3 patient receive cyclophosphamide day -1 first cycle ( one day prior first infusion Sipuleucel-T ) . All patient receive Sipuleucel-T cell infusion Day 0 . The Sipuleucel-T cell infusion repeat every two week total three cycle . If Sipuleucel-T active cellular immunotherapy apheresis obtain infusion cyclophosphamide , meet FDA approve Certificate Analysis ( COA ) release criterion Dendreon , generate , second apheresis perform . Failure two attempt generate Sipuleucel-T product two aphereses either 2nd 3rd schedule Sipuleucel-T infusion consider failure one patient meet release criterion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histopathological documentation prostate cancer prior start study . Patients must metastatic progressive castrateresistant prostate cancer define progressive disease ( see ) despite surgical castration ongoing use gonadotropinreleasing hormone agonist confirm castrate level testosterone . Criteria progression trial eligibility define Prostate Cancer Clinical Trials Working Group253 . Clinically progressive prostate cancer must evidence document follow parameter : 1 . Two consecutively rise PSA value minimum 1week interval ( 2.0 ng/mL minimum start value PSA ) 2 . Appearance one new lesion bone scan 3 . Progressive measurable disease RECIST 1.1 Patients flutamide least 6 month must disease progression least 4 week withdrawal . Patients bicalutamide nilutamide least 6 month must progression least 6 week withdrawal.2.1.1.4 Performance Status : ECOG 01 Karnofsky 80100 % ( asymptomatic minimally symptomatic metastatic disease ) . No previous chemotherapy use . No therapeutic immunosuppression immunomodulation alter bone marrow function within 6 week prior study entry e.g . GCSF , GMCSF , EPO , prednisone etc . Must adequate : Bone marrow function : Absolute neutrophil count ( ANC ) great equal 1,500/mcl . Platelets great equal 100,000/mcl . Renal function : Creatinine le equal 1.5 time institutional upper limit normal ( ULN ) Hepatic function : Bilirubin le equal 1.5 x ULN ( CTCAE v4.0 grade 1 ) except patient Gilbert 's disease ( 5.0 mg/dL ) . SGOT alkaline phosphatase less equal 2.5 x ULN . Normal Cardiac function : ECG evidence arrhythmia , conduction abnormality ischemia . No active coronary artery disease ; New York Heart Association class II , III IV disease ; arrhythmia require treatment . Must willing able sign inform consent document explain neoplastic nature disease , procedures follow , experimental nature treatment , alternative treatment potential risk toxicity . EXCLUSION CRITERIA : Concurrent treatment cancer therapy include radiation ( except palliative radiation therapy bone metastasis ) , chemotherapy investigational agent ( ) . Androgen suppression therapy allow . History second active malignancy last 2 year nonmelanoma skin cancer . Patients active history autoimmune disease/symptom/conditions include : type I diabetes , rheumatoid arthritis , systemic lupus erythematosus ( SLE ) , ulcerative colitis , Crohn 's Disease , multiple sclerosis ( MS ) , ankylose spondylitis . Type II diabetes mellitus , vitiligo stable hypothyroidism consider exclusion criterion . Patients chronically treat immunosuppressive drug cyclosporin , adrenocorticotropic hormone ( ACTH ) . Concurrent use systemic glucocorticoid within 4 week prior trial entry Patients acquire , hereditary , congenital immunodeficiency include cellular immunodeficiency , hypogammaglobulinemia dysgammaglobulinemia . CNS , lung , liver metastasis , poor prognosis , potential inability meet study endpoint . Serious active infection time prestudy screen . Positive HIV Hepatitis C antibodies Hepatitis B anticore antibody , immunotherapy rely intact immune system , toxicity may exacerbate presence infection .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Anti PD-1 Monoclonal Antibody</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Autologous Cellular Immunotherapy</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>